The above chart presents the market trend analysis for chemi from 2025 to 2026.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2026, the company has completed 53 transactions, with a transaction quantity of 41486 and a transaction weight of 67924.
chemi is International Buyer&Supplier,
and primarily engages in the import and export business of products such as mesalamine,pharmaceutical,packaged.
According to the 52wmb.com global trade database, as of 2026-07-12, the company has completed 2269 international trades,
with its main trading regions covering united states,other,india etc.
The core products include HS29225090,HS330420,HS300680 etc,
often transported via genoa,port rotterdam, port busan etc,
and its main trading partners are teva usa pharmaceuticals usa inc.,zydus pharmaceuticals usa inc.,eversana life science services llc.
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on chemi is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.